Dysregulation of secretion of CXC α-chemokine CXCL10 in papillary thyroid cancer: Modulation by peroxisome proliferator-activated receptor-γ agonists

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1299-1311

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Fallahi, Poupak ^a   Frascerra, Silvia ^a   Piaggi, Simona ^a   Gelmini, Stefania ^b   Lupi, Cristiana ^a   Minuto, Michele ^a   Berti, Piero ^a   Benvenga, Salvatore ^c   Basolo, Fulvio ^a   Orlando, Claudio ^b   Miccoli, Paolo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLITAZONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PROTEIN SECRETION; THYROID FOLLICLE CELL; THYROID PAPILLARY CARCINOMA; TRANSCRIPTION REGULATION; UPREGULATION;

APOPTOSIS; CARCINOMA, PAPILLARY; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL10; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; INTERFERON-GAMMA; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLIDINEDIONES; THYROID GLAND; THYROID NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 72549106749     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0337     Document Type: Article

References (44)

1. Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R & Belfiore A 2006 Peroxisomal proliferator-activated receptor-γ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147 4463-4475. (Pubitemid 44268398)
2. Andrews NC & Faller DV 1991 A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Research 19 2499.
3. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E & Serio M 2004 High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. Journal of Clinical Endocrinology and Metabolism 89 5496-5499. (Pubitemid 39518431)
4. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E & Serio M 2005 Increase of interferon-γ inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. European Journal of Endocrinology 152 171-177. (Pubitemid 40309561)
5. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M & Ferrannini E 2006 Interferon-γ-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. Journal of Clinical Endocrinology and Metabolism 91 614-620. (Pubitemid 43236933)
6. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Marchetti I, Ugolini C, Basolo F, Miccoli P & Ferrannini E 2008a Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. European Journal of Endocrinology 159 283-291.
7. Antonelli A, Fallahi P, Ferrari SM, Carpi A, Berti P, Materazzi G, Minuto M, Guastalli M & Miccoli P 2008b Dedifferentiated thyroid cancer: a therapeutic challenge. Biomedicine and Pharmacotherapy 62 559-563.
8. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Barani L, Marchetti I, Ferrannini E & Miccoli P 2008c Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clinical Endocrinology 69 148-152.
9. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Minuto M, Giannini R, Marchetti I, Barani L, Basolo F et al. 2009 Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clinical Endocrinology 70 946-953.
10. Benvenga S 2008 Update on thyroid cancer. Hormone and Metabolic Research 40 323-328.
11. Dewald B, Moser B, Barella L, Schumacher C, Baggiolini M & Clark-Lewis I 1992 IP-10, a γ-interferon-inducible protein related to interleukin-8, lacks neutrophil activating properties. Immunology Letters 32 81-84.
12. Frohlich E, Machicao F & Wahl R 2005 Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocrine-Related Cancer 12 291-303. (Pubitemid 40896448)
13. Garcia-Bates TM, Lehmann GM, Simpson-Haidaris PJ, Bernstein SH, Sime PJ & Phipps RP 2008 Role of peroxisome proliferator-activated receptor γ and its ligands in the treatment of hematological malignancies. PPAR Research 2008 834612.
14. Garcià-Lòpez MA, Sancho D, Sànchez-Madrid F & Marazuela M 2001 Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. Journal of Clinical Endocrinology and Metabolism 86 5008-5016. (Pubitemid 33020557)
15. Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, Pestel J, Tonnel AB & Trottein F 2001 Peroxisome proliferator-activated receptor γ activators affect the maturation of human monocyte-derived dendritic cells. European Journal of Immunology 31 2857-2865. (Pubitemid 32994536)
16. Grommes C, Landreth GE & Heneka MT 2004 Antineoplastic effects of peroxisome proliferator activated receptor-γ agonists. Lancet Oncology 5 419-429. (Pubitemid 38878045)
17. Gutiérrez-Cañas I, Rodrìguez-Henche N, Bolaños O, Carmena MJ, Prieto JC & Juarranz MG 2003 VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. British Journal of Pharmacology 139 1050-1058. (Pubitemid 36877404)
18. Hayashi N, Nakamori S, Hiraoka N, Tsujie M, Xundi X, Takano T, Amino N, Sakon M & Monden M 2004 Antitumor effects of peroxisome proliferator activate receptor γ ligands on anaplastic thyroid carcinoma. International Journal of Oncology 24 89-95.
19. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF & Weetman AP 2003 Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clinical Endocrinology 59 207-213. (Pubitemid 36918657)
20. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM & Haugen BR 2004 Retinoid X receptor-γ and peroxisome proliferator-activated receptor-γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Molecular Cancer Therapeutics 3 1011-1020. (Pubitemid 39199596)
21. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM & Fletcher JA 2000 PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science 289 1357-1360. (Pubitemid 30656054)
22. Laemmli UK 1970 Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 680-685.
23. -ΔΔCt. Methods 25 402-408.
24. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M & Moser B 1996 Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. Journal of Experimental Medicine 184 963-969. (Pubitemid 26313554)
25. Lombardi A, Cantini G, Piscitelli E, Gelmini S, Francalanci M, Mello T, Ceni E, Varano G, Forti G, Rotondi M et al. 2008 A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-γ inflammatory effects in human endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 28 718-724.
26. Luster AD 1998 Chemokines - chemotactic cytokines that mediate inflammation. New England Journal of Medicine 338 436-445.
27. Mackay CR 1996 Chemokine receptors and T cell chemotaxis. Journal of Experimental Medicine 184 799-802.
28. Martelli ML, Iuliano R, Le Pera I, Sama I, Monaco C, Cammarota S, Kroll T, Chiariotti L, Santoro M & Fusco A 2002 Inhibitory effects of peroxisome poliferator-activated receptor γ on thyroid carcinoma cell growth. Journal of Clinical Endocrinology and Metabolism 87 4728-4735. (Pubitemid 35247068)
29. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J & Luster AD 2000 Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. Journal of Immunology 164 6503-6508. (Pubitemid 30408835)
30. McCall KD, Harii N, Lewis CJ, Malgor R, Kim WB, Saji M, Kohn AD, Moon RT & Kohn LD 2007 High basal levels of functional Toll-like receptor 3 (TLR3) and noncanonical Wnt5a are expressed in papillary thyroid cancer and are coordinately decreased by phenylmethimazole together with cell proliferation and migration. Endocrinology 148 4226-4237. (Pubitemid 47295676)
31. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M et al. 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation 115 1068-1081.
32. Ohta K, Endo T, Haraguchi K, Hershman JM & Onaya T 2001 Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. Journal of Clinical Endocrinology and Metabolism 86 2170-2177. (Pubitemid 32472935)
33. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY & Clark OH 2005 Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15 222-231. (Pubitemid 40418689)
34. Philips JC, Petite C, Willi JP, Buchegger F & Meier CA 2004 Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nuclear Medicine Communications 25 1183-1186. (Pubitemid 39614279)
35. Puxeddu E, Knauf JA, Sartor MA, Mitsutake N, Smith EP, Medvedovic M, Tomlinson CR, Moretti S & Fagin JA 2005 RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocrine-Related Cancer 12 319-334. (Pubitemid 40896450)
36. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M et al. 2002 Expression of IP-10/CXCL10 and Mig/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in the serum of subjects with recent onset Graves'disease. American Journal of Pathology 161 195-206. (Pubitemid 34760785)
37. Ruffini PA, Morandi P, Cabioglu N, Altundag K & Cristofanilli M 2007 Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 109 2392-2394.
38. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM & Santoro M 2006 BRAF is a therapeutic target in aggressive thyroid carcinoma. Clinical Cancer Research 12 1623-1629.
39. Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D & Saubermann LJ 2005 Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-γ ligands on T Helper Type 1 chemokine regulation include nontranscriptional control mechanisms. Inflammatory Bowel Diseases 11 244-252. (Pubitemid 40439678)
40. Schmid I, Uittenbogaart C & Jamieson BD 2007 Live-cell assay for detection of apoptosis by dual-laser flow cytometry using Hoechst 33342 and 7-amino-actinomycin D. Nature Protocols 2 187-190. (Pubitemid 47040082)
41. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC et al. 2008 Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. Journal of Clinical Endocrinology and Metabolism 93 4331-4341. (Pubitemid 352789529)
42. Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Matsushima K, Kelvin DJ & Oppenheim JJ 1993 Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. Journal of Experimental Medicine 177 1809-1814. (Pubitemid 23146150)
43. Towbin H, Staehelin T & Gordon J 1979 Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. PNAS 76 4350-4354. (Pubitemid 9256559)
44. Yang XY, Wang LH & Farrar WL 2008 A role for PPARγ in the regulation of cytokines in immune cells and cancer. PPAR Research 2008 961753.